Progress is being made in the fight
against cancer – the 10th leading cause of death worldwide in 2003,
according to the World Health Organization. Many cancer researchers
use the Agilent DNA microarray platform for gene expression profiling to
how cancer begins, develops and progresses. Agilent now is developing
specialized DNA microarrays for comparative genomic hybridization (CGH),
that allows researchers to study chromosomal changes in cancer
and informs them about progression of patients in a way never before possible.
Labs is working with scientists in other research organizations,
such as the Translational Genomics Research Institute, to
develop commercial CGH solutions. The solutions use Agilent’s ink-jet DNA
microarray manufacturing process, in which short strands of DNA called
base by base directly on a glass slide.